Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | CTSC | P53634 | 2/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | PAM | P19021 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28274418 | 0.99 | HTR2C (0.46) | HTR2CHTR2BCTSCELANEPOLB | |
| SCHEMBL7582887 | 0.86 | TDP1 (0.46) | HTR2CHTR2BCTSCELANEALDH1A1 | |
| SCHEMBL7381636 | 0.86 | CTSC (0.47) | HTR2CHTR2BCTSCELANEPOLB | |
| SCHEMBL11561585 | 0.82 | CTSC (0.49) | HTR2CHTR2BCTSCELANECYP1A2 | |
| SCHEMBL11509393 | 0.81 | DPP4 (0.42) | HTR2CHTR2BCTSCELANETSHR | |
| SCHEMBL11547645 | 0.81 | HTR2C (0.42) | HTR2CHTR2BCTSCELANETSHR | |
| SCHEMBL3447413 | 0.81 | TSHR (0.51) | HTR2CHTR2BCTSCELANEALDH1A1 | |
| SCHEMBL11421884 | 0.81 | HTR2C (0.48) | HTR2CHTR2BELANEALDH1A1DPP4 | |
| SCHEMBL489770 | 0.81 | TSHR (0.51) | HTR2CHTR2BCTSCELANEALDH1A1 | |
| Proline SCHEMBL6040134 | 0.81 | HTR2C (0.48) | HTR2CHTR2BCTSCALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220356182-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2022-11-10 | — | — | US | disclosed |
| CN-109369494-A | A kind of preparation method of N- phenylacetyl group-L-PROLINE | 中北大学 | 2019-02-22 | — | — | CN | disclosed |
| CN-104788352-A | Preparation methods of N-phenylacetyl-L-proline, and N-(1-(phenylacetyl)-L-prolyl)glycine ethyl ester | SHANGHAI XUXIN CHEMICAL CO LTD | 2015-07-22 | — | — | CN | disclosed |
| US-8143288-B2 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| EP-2410844-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | Merck Sharp & Dohme Corp. (US) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010111483-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2010-09-30 | — | — | WO | disclosed |
| EP-1893573-B1 | INHIBITORS OF HCV REPLICATION | BRISTOL MYERS SQUIBB CO (US) | 2010-07-21 | — | — | EP | disclosed |
| EP-1893573-A1 | INHIBITORS OF HCV REPLICATION | Brystol-Myers Squibb Company (US) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006133326-A1 | INHIBITORS OF HCV REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-14 | — | — | WO | disclosed |
| US-20060276511-A1 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220356182-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | HTR2C 4424/4885HTR2B 4767/4885CTSC 127/4885 |
| US-20060276511-A1 | Inhibitors of HCV replication | EIF2AK2, RTF2, GTF3C1 | HTR2C 3666/4885HTR2B 4086/4885CTSC 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.